“A viable space tourism business is what you pay for today … but a chance to disrupt the multi-trillion-dollar airline [total addressable market] is what is really likely to drive the upside,” Morgan Stanley analyst Adam Jonas wrote in a note to investors.
Read MoreBiogen shares rise after the biotech firm offers more data on its late-stage Alzheimer’s drug, aducanumab.
Analysts who parsed through it say the lack of any new negatives in the report means that they expect the company will take the data to the Food and Drug Administration.
